Stanford University and Mount Sinai's Icahn School of Medicine announced that their joint project, Biomni-AD, secured a $1 million grand prize at the 20th International Conference on Alzheimer's and Parkinson's Diseases in Copenhagen on March 20. Awarded by the Alzheimer's Disease Data Initiative, the honor recognized Biomni-AD as one of only two winners selected from over 180 global submissions. The system functions as an AI co-scientist designed to accelerate Alzheimer's research by synthesizing vast amounts of complex biological data. Gregory Moore, head of the judging panel, noted that finalists were evaluated on scientific rigor and the potential to materially advance discovery and treatments. Biomni-AD distinguished itself by acting as an active research partner rather than a simple tool for specific queries. Professor Jure Leskovec, a member of the team, explained that while most AI tools answer specific questions, Biomni-AD can explore hypotheses, integrate evidence across genetic, protein, neuroimaging, and clinical data modalities, and communicate its reasoning for human scientists to interrogate and expand upon. Lead developer Kexin Huang emphasized the scientist-first philosophy, describing the agent as a collaborative infrastructure built to help researchers accomplish their work efficiently. The development of such an agent presented significant technical challenges, particularly in teaching the AI to reason like a scientist rather than merely retrieving data or matching patterns. The need for such advanced tools is urgent, as Alzheimer's disease is projected to affect approximately 152 million people globally by 2050. The complexity of the disease, requiring the simultaneous synthesis of diverse data types, often exceeds the capacity of any individual human researcher. Biomni-AD aims to address this by holding the full complexity of the disease in its working memory and acting as a tireless collaborator. The motivation for the project also carries personal significance for Huang, who carries the APOE gene variant associated with a high risk of developing Alzheimer's disease. With the prize funding, the team plans to continue refining Biomni-AD and make it freely available to researchers worldwide through the AD Workbench platform. Leskovec expressed hope that the project will shift the broader conversation in AI medicine away from solely focusing on drug discovery or diagnosis, toward augmenting how scientists conduct their daily work. The team envisions a future where AI provides researchers with a knowledgeable, always-available partner capable of managing the intricate details of disease research.